- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE HealthCare Debuts New PET/MRI System at SNMMI Conference
The newly launched Signa PET/MR Air device offers technological features that may bolster image quality and enhance diagnostic accuracy for diseases such as prostate cancer and Alzheimer’s disease.
Offering a variety of reported technological advances to facilitate the diagnosis of conditions such as Alzheimer’s disease and prostate cancer, the Signa PET/MR Air system (GE HealthCare) will be launched at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
The Signa PET/MR Air system combines the high sensitivity of positron emission tomography (PET) with the anatomical precision offered by magnetic resonance imaging (MRI) in one device, according to GE HealthCare. The company said integrating prostate-specific membrane antigen (PSMA)-targeted PET radiotracer agents with the Signa PET/MR Air system may help optimize staging and facilitate a more precise diagnosis in prostate cancer cases.
GE HealthCare said integrating prostate-specific membrane antigen (PSMA)-targeted PET radiotracer agents with the newly launched Signa PET/MR Air system (shown above) may help optimize staging and facilitate a more precise diagnosis in prostate cancer cases. (Image courtesy of GE HealthCare)
Other features of the Signa PET/MR Air system include the Time-of-Flight (TOF) PET detector and MotionFree Brain PET. Addressing patient motion during exams without external tracking devices, MotionFree Brain PET enables consistent image quality, which reduces repeat scans and may potentially improve diagnostic accuracy for challenging patients, according to the company. GE HealthCare added that the sensitivity of the ToF PET detector can detect adverse effects in a single scan and provide insights into disease progression.
“Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer’s disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring,” noted Jie Xue, president and CEO of MR at GE HealthCare. “We are excited to see SIGNA PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalized care.”
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
